XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update




XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

Clinical Data doubles known genetic factors associated with urate and Gout

CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked to the over-expression of xanthine oxidase (“XO”), high chronic uric acid concentrations in the blood and gout. These ground breaking findings further support the Company’s approach to treating gout, kidney and other diseases by inhibiting XO.

Historically, high uric acid concentration in the blood has been associated with increased incidence of gout, inflammation and health consequences, attributed to diet and lifestyle choices. Xanthine oxidase is an essential enzyme within the uric acid metabolic pathway and is required for the breakdown of purine nucleotides. The breakdown products of XO, uric acid and reactive oxygen species, are released during the enzymatic reaction and may play a detrimental role in the circulatory system and within tissue during disease. XORTX-sponsored discoveries in rodent models of gout and polycystic kidney disease (“PKD”) implicate over-expression or over-activity of XO as a potentially important target in treating this disease. Gout is a chronic disease that is caused by an innate immune response to deposits of uric acid crystals when uric acid is high.

Recent work by TJ Major and colleagues presented evidence that in a large clinical study of 2.6 million individuals that as many as 410 genetic factors (including 149 new factors) are associated with molecular mechanisms of the inflammatory component of gout¹. This clinical study aligns closely with evidence for over-expression of XO in human² and with work by Wang et al. suggests linkage of genetic factors to PKD². Recently, new emerging discoveries link genetic factors to specific populations and show that higher XO expression is associated with a variety of conditions including hyperuricemia³, sepsis, organ failure and sepsis associated acute respiratory distress syndrome (ARDS)^4,5, kidney dysfunction^3,4, diabetes⁵, polycystic kidney disease^2,6 and kidney failure^7,8. From a mechanistic standpoint, these studies advocate for a precision medicine approach in which genetic risk variants would guide treatment decisions².

Commenting on the research, Allen Davidoff, Ph.D., Chief Executive Officer of XORTX, stated, “This pioneering into the health consequences of hyperuricemia and linkage to genetic factor in gout and autosomal dominant polycystic kidney disease (ADPKD) sponsored by XORTX and these peer-reviewed, published research papers support our belief that pharmacologic targeting of XO holds enormous therapeutic potential, specifically where increased XO activity is associated with non-diabetic or diabetic kidney diseases. These discoveries highlight an opportunity to develop a personalized therapeutic approach for individuals whose unique genetic factors predispose them to disease, and the need for xanthine oxidase inhibition to treat those individuals at risk. We believe that XORTX’s expertise in developing XO inhibitors, protected by a patent portfolio that anticipated this opportunity, combined with our therapeutic platform is ideally positioned to deliver targeted therapeutics to individuals. Our planned clinical trial using our commercial formulation of oxypurinol will bring us ever closer preparing a NDA (new drug application) for this important gout therapy.”

Corporate Updates – Board Changes, Financing and Vectus

XORTX announces the appointment of Krysta Davies Foss as a director and the resignation of Bill Farley, Abigail Jenkins and Patrick Treanor reducing the board to five members. Ms. Davies Foss is a seasoned biotechnology executive with more than 25 years of experience advising pharmaceutical and biotechnology companies on development strategy, commercialization, and market preparedness across a broad range of therapeutic areas. She currently serves as Chief Executive Officer of Triad Strategic Services, a leading pharma and biotech strategy consulting firm. In addition to her executive role, Ms. Davies Foss serves on multiple boards, including the Canadian Organization for Rare Disorders (CORD), and has provided strategic intelligence and advisory services to organizations ranging from incubators and early-stage startups to large multinational pharmaceutical companies. Her experience spans the full product development lifecycle, from early innovation through global commercialization.

Dr Allen Davidoff stated, “The addition of Ms. Foss adds a strong board member to the Company. Her depth of strategic insight and industry leadership will be a valuable asset as the Company advances its clinical programs and long-term growth strategy. The Company wishes to thank Bill Farley, Abigail Jenkins and Pat Treanor for their efforts on behalf of XORTX over the past several years.”

The Company also wishes to clarify its disclosure included in its news release of October 29, 2025 announcing the closing of the US$1.1 million Registered Direct Offering (the “Offering”). In that news release, the number of pre-funded warrants of 1,117,530 was incorrect. On closing, the Company issued 572,470 common shares and 1,177,530, a difference of 60,000 pre-funded warrants, for total aggregate common shares and pre-funded warrants of 1,750,000. Further, the Company confirms that in addition to the 87,500 agent warrants granted to D. Boral Capital LLC exercisable at USD$0.69 per common share commencing 181 days following issuance for a period of 18 months, D. Boral Capital LLC was also paid a cash commission of USD$77,175, equal to 7% of the gross proceeds of the Offering.

Finally, the Company wishes to provide an update on timing for closing its acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited’s (“Vectus”), an Australian Securities Exchange (“ASX”) listed company that was announced on October 17, 2025. Vectus is awaiting approval from the ASX on whether shareholder approval is required for the sale of the VB4-P5 intellectual property. Pursuant to the binding term sheet that was entered into between XORTX and Vectus, closing is to occur no later than 90 days post signing, being January 13, 2026. XORTX and Vectus remain committed to finalizing the acquisition. The Company will provide additional updates on timing for closing when clarity on ASX approval is received by Vectus.

References:

1. Major TJ, et al, A genome-wide association analysis reveals new pathogenic pathways in gout, Nature Genetics, 56, 2392-2406, 2024
2. Korsmo HW, Emerging roles of xanthine oxidoreductase in chronic kidney disease, Antioxidants, June 2024
3. Major TJ, et al Evaluation of the diet wide contribution to serum urate levels: Met-analysis of population based cohorts, BMJ, 363, k3952, 2018
4. Gao, Li et al., Xanthine oxidoreductase gene polymorphism are associated with high risk of sepsis and organ failure, Respir. Res, 24, 177_2023
5. Liu H, et al., Genetic variants in XDH are associated with prognosis off gastric cancer in a Chines population, 663, 196, 2013
6. Wang et al., Genetic susceptibility to diabetic kidney disease is linked to promoter variants of XOR.” The authors identified an expression quantitative trait loci (QTL) in the cis-acting regulatory region of the xanthine dehydrogenase, or xanthine oxidoreductase (XO), a binding site for C/EBPβ, to be associated with diabetes-induced podocyte loss in diabetic kidney disease in male mice. They concluded that certain types of alleles of a gene that controls the expression of xanthine oxidase can be over expressed in CKD, diabetic kidney disease and polycystic kidney disease.
7. Kudo M et al., Functional Characterization of Genetic Polymorphisms Identified in the Promotor Region of the Xanthine Oxidase Gene, Drug Metab. Pharmacokinet., 25, 599, 2010
8. Boban M, et al., Circulating purine compound, uric acid, and xanthine oxidase/dehydrogenate relationship in essential hypertension and end stage renal disease., Ren. Fail., 36, 613, 2014

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.

Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. 

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC’s website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules




Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or pre-funded warrant) and associated Series K-1warrants and Series K-2 warrants, for expected gross proceeds to INBS of approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The Series K-1 warrants and Series K-2 warrants will have an exercise price of $4.10 per share of common stock and will be exercisable immediately upon issuance. The Series K-1 warrants and Series K-2 warrants will each have a term of five years following the date a registration statement registering all warrant shares underlying the Series K-1 warrants and Series K-2 warrants is declared effective by the United States Securities and Exchange Commission (the “SEC”).

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the private placement.

The closing of the private placement is expected to occur on or about January 2, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement for working capital and for general corporate purposes.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file an initial registration statement with the SEC covering the resale of the shares of common stock to be issued to the investors (including the shares of common stock issuable upon the exercise of the warrants) no later than 10 calendar days following the date of the agreement and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 45 days after the date of such agreement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: http://www.ibs.inc/

Forward-Looking Statements:

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to consummate the proposed transaction described in this press release, develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:

Intelligent Bio Solutions Inc.
info@ibs.inc

Investor & Media Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com

LuluTox Detox Tea Unveiled: Why Lulutox Tea Being Discussed as the Best Herbal Weight Loss Tea Blend for Women to Burn Fat in 2026




LuluTox Detox Tea Unveiled: Why Lulutox Tea Being Discussed as the Best Herbal Weight Loss Tea Blend for Women to Burn Fat in 2026

Discover Lulutox Detox Tea, a herbal blend designed to support digestion, detox balance, and daily wellness. Ingredients, usage, and availability explained.

New York City,, Dec. 31, 2025 (GLOBE NEWSWIRE) — Intro

As global wellness markets move into 2026, herbal detox and functional tea formulations are gaining renewed attention amid rising consumer interest in plant-based metabolic and digestive support. Industry data continues to highlight increased demand for gentle, non-synthetic wellness beverages positioned for daily use. Within this landscape, Lulutox Detox Tea has entered wider distribution channels and is now being discussed across press and health publications as part of the evolving herbal detox category.

Recent announcements surrounding expanded availability and formulation transparency have brought Lulutox Detox Tea into focus as a structured herbal blend designed to support digestive cleansing, metabolic efficiency, and routine wellness maintenance. Unlike conventional stimulant-heavy products, the formulation aligns with a broader industry shift toward botanical combinations traditionally associated with digestion, circulation, and natural detox pathways.

Visit the Official Lulutox Detox Tea Website

What Is Lulutox Detox Tea?

Lulutox Detox Tea is a herbal tea formulation developed to support natural detoxification processes through a blend of plant-based ingredients traditionally associated with digestive balance and metabolic support. The product is presented as a daily tea infusion, formulated for routine consumption rather than short-term or aggressive cleansing cycles.

Positioned within the functional beverage category, Lulutox Detox Tea combines multiple herbs commonly referenced in wellness literature for their role in digestion, gut comfort, and internal cleansing. The formulation avoids synthetic additives and is designed to function as a supportive wellness beverage rather than a medicinal intervention.

From a product design perspective, Lulutox Detox Tea is intended to complement lifestyle-based wellness approaches, including balanced nutrition and hydration. Its tea-based delivery format allows for gradual botanical absorption while supporting hydration, an element often emphasized in detox-focused wellness strategies.

The tea is packaged for convenience and consistency, allowing users to prepare a standardized infusion using hot water. This delivery method aligns with longstanding herbal traditions while maintaining modern manufacturing and quality standards. Lulutox Detox Tea is not positioned as a rapid or extreme detox product, but rather as a structured herbal blend suitable for ongoing use.

Everything you should know about Lulutox Detox Tea—from ingredients to proper use.

Why Lulutox Detox Tea Is Being Discussed as a Herbal Weight Loss Option for Women

Within wellness industry discussions, Lulutox Detox Tea is frequently referenced in relation to metabolic and digestive support, two functional areas commonly associated with weight-management routines. Herbal teas formulated with digestive and cleansing botanicals are often positioned as complementary tools in broader wellness programs focused on balance rather than rapid weight change.

Lulutox Detox Tea’s formulation emphasizes herbs traditionally associated with gut comfort, fluid balance, and metabolic efficiency. These functions are commonly highlighted in wellness research as supportive elements for managing bloating, digestive sluggishness, and water retention—factors that can influence perceived weight changes.

The tea’s stimulant-moderate formulation aligns with increasing demand for gentler wellness products designed for regular use. Rather than targeting aggressive fat-burning claims, Lulutox Detox Tea is positioned around internal balance, digestive clarity, and daily metabolic support, which are frequently cited priorities in women’s wellness frameworks.

By focusing on botanical support mechanisms rather than pharmaceutical stimulation, the product reflects broader trends in herbal weight-management discussions, particularly those centered on long-term metabolic wellness rather than short-term interventions.

See why Lulutox Detox Tea is gaining attention in Australia as a herbal weight-loss tea blend for women.

Key Herbal Ingredients in LuluTox Detox Tea

Lulutox Detox Tea is formulated using a structured blend of botanical ingredients traditionally associated with digestive balance, internal cleansing, and metabolic support. The formulation strategy centers on combining herbs that work synergistically rather than relying on a single dominant compound. Each ingredient is selected based on its historical use in herbal wellness systems and its compatibility within a tea-based delivery format.

Key herbal components commonly associated with Lulutox Detox Tea include:

• Dandelion Leaf – Widely referenced in herbal literature for its role in supporting liver function and natural detox pathways. Often included in wellness teas for fluid balance and internal cleansing support.
• Ginger Root – Traditionally used to support digestion and gastrointestinal comfort. Ginger is commonly associated with metabolic stimulation and improved digestive flow.
• Green Tea Extract – Known for its natural antioxidant content and mild metabolic-support properties. Green tea is frequently included in wellness formulations targeting energy balance and fat metabolism.
• Peppermint Leaf – Often used to promote digestive ease and reduce sensations of bloating. Peppermint supports gastrointestinal relaxation and palatability.
• Licorice Root – Traditionally included to support gut lining comfort and balance herbal formulations. Licorice root is commonly used to harmonize herbal blends.
• Fennel Seed – Frequently associated with digestive regularity and gas reduction. Fennel supports smooth digestive transit.
• Senna Leaf (in controlled amounts) – Included in many detox teas for its role in supporting elimination processes. Its usage is carefully balanced to maintain gentleness.

The ingredient blend is designed to steep efficiently, allowing water-soluble plant compounds to infuse evenly. This approach supports consistency, tolerability, and daily usability, aligning with modern wellness expectations for herbal detox beverages.

Looking into Lulutox Detox Tea? Explore how this herbal blend fits into modern wellness routines.

How Lulutox Detox Tea Is Designed to Work

Lulutox Detox Tea is designed to support the body’s natural detoxification and digestive processes through gentle botanical interaction rather than aggressive stimulation. Its tea-based delivery system emphasizes hydration as a foundational component of detox support, while herbal compounds complement internal metabolic and digestive activity.

Once prepared, the infused tea delivers water-soluble plant compounds that interact with digestive pathways. These compounds are commonly associated with stimulating digestive flow, supporting liver-related detox mechanisms, and promoting regular elimination. The formulation avoids reliance on synthetic stimulants, instead focusing on gradual botanical support.

The tea’s functional design prioritizes consistency over intensity. Rather than triggering abrupt detox responses, Lulutox Detox Tea is structured to be consumed regularly, allowing cumulative effects to support internal balance over time. This aligns with wellness frameworks that emphasize long-term metabolic and digestive stability.

Herbal components such as green tea and ginger are commonly associated with thermogenic and metabolic support, while ingredients like peppermint and fennel focus on gastrointestinal comfort. Together, they create a balanced formulation aimed at supporting digestion, fluid balance, and metabolic clarity.

By integrating hydration with herbal functionality, Lulutox Detox Tea works within existing physiological processes, supporting natural detox rhythms rather than overriding them. This approach reflects current industry trends favoring sustainable, plant-based wellness solutions.

Thinking about adding a detox tea to your routine? Learn what Lulutox Detox Tea offers.

Potential Benefits of LuluTox Detox Tea

Lulutox Detox Tea is formulated to provide a range of wellness-supporting benefits commonly associated with herbal detox beverages. Its primary functional focus areas include digestion, metabolic efficiency, internal cleansing, and daily wellness balance.

One of the central benefits is digestive support. Herbal ingredients traditionally linked to digestive stimulation and gut comfort may help promote smoother digestion and reduce sensations of heaviness or bloating. This digestive clarity is often emphasized as foundational to overall wellness.

The formulation also supports internal detox pathways by assisting the body’s natural elimination processes. Herbs associated with liver support and fluid balance may contribute to gentle cleansing without extreme or disruptive effects.

Metabolic support is another functional area addressed through ingredients such as green tea and ginger. These botanicals are frequently referenced in wellness research for their role in energy utilization and metabolic activity, contributing to daily vitality.

Hydration plays a complementary role in these benefits. As a tea-based product, Lulutox Detox Tea encourages regular fluid intake, which is essential for detoxification and digestive efficiency.

Collectively, these benefits position Lulutox Detox Tea as a daily wellness beverage designed to support balance rather than rapid or extreme detox outcomes.

Where to Buy Lulutox Detox Tea and Availability Updates

Lulutox Detox Tea is made available through official online Website to maintain product authenticity and formulation consistency. Purchasing through official website ensures access to accurate product descriptions, batch integrity, and updated availability information.

Recent distribution updates indicate expanded market availability across multiple regions, reflecting growing demand for herbal detox solutions. Online access allows for centralized order fulfillment and consistent quality control.

Availability updates are periodically released to reflect inventory status, regional shipping options, and official product announcements. Consumers are advised to rely on official website to ensure they receive the correct formulation and packaging.

How to Use LuluTox Detox Tea for Best Results

Lulutox Detox Tea is designed to be incorporated into a daily wellness routine through a simple and consistent preparation process. As a tea-based formulation, its effectiveness is closely tied to proper infusion, regular use, and alignment with general hydration and lifestyle practices.

To prepare Lulutox Detox Tea, one serving is typically steeped in freshly heated water for the recommended duration. Allowing adequate steep time enables the herbal ingredients to fully infuse, ensuring a balanced release of plant-based compounds into the beverage. The tea is intended to be consumed warm, though it may also be allowed to cool depending on individual preference.

For routine use, Lulutox Detox Tea is generally consumed once per day. Consistency is emphasized over frequency, as the formulation is structured to support gradual digestive and metabolic processes rather than immediate or intense effects. Incorporating the tea at the same time each day may help support a steady wellness rhythm.

Hydration plays an important role in maximizing the intended function of the tea. As with most detox-oriented beverages, adequate daily water intake supports internal cleansing and digestive efficiency. The tea is not intended to replace meals or fluids but to complement a balanced hydration routine.

Lulutox Detox Tea is designed for ongoing use rather than short-term detox cycles. This aligns with modern wellness approaches that prioritize sustainable, plant-based support over abrupt interventions. Individuals incorporating the tea into their routine are generally advised to maintain a balanced diet and active lifestyle, as the product is formulated to support—not substitute—broader wellness habits.

By following these usage guidelines, Lulutox Detox Tea can be consistently integrated into daily routines as a supportive herbal beverage within a structured wellness framework

A closer look at Lulutox Detox Tea and its role in today’s herbal detox trend.

Frequently Asked Questions About Lulutox Detox Tea

What is Lulutox Detox Tea designed for?
It is formulated to support digestion, internal cleansing, and metabolic balance.

How often should it be consumed?
Typically once per day as part of a regular wellness routine.

Is it stimulant-heavy?
The formulation emphasizes botanical balance rather than aggressive stimulation.

Can it be used long term?
It is designed for ongoing, routine use.

Does it replace diet or exercise?
No. It is intended to complement a balanced lifestyle.

Lulutox Detox Tea Customer Reviews

Emma R., Sydney, Australia
“I incorporated Lulutox Detox Tea into my daily routine as part of a broader wellness reset. What stood out most was how easy it was to use consistently. The tea fits naturally into my morning schedule and feels gentle rather than overwhelming. Over time, I noticed a greater sense of digestive balance and daily comfort, which made it easier to stay on track with my routine. It feels like a supportive wellness beverage rather than something extreme.”

Charlotte M., Manchester, United Kingdom
“LuluTox Detox Tea has become a regular part of my evening routine. I was looking for a herbal tea that aligned with my preference for plant-based wellness products, and this one felt well thought out. The formulation feels balanced, and I appreciate that it’s designed for ongoing use rather than short-term cleanses. It complements my lifestyle without requiring major adjustments.”

Hannah L., Melbourne, Australia
“What I appreciate about Lulutox Detox Tea is its simplicity. Preparation is straightforward, and the tea fits easily into my daily schedule. It feels like a gentle wellness addition that supports hydration and routine consistency. I prefer products that focus on balance, and this tea aligns well with that approach.”

Rebecca T., Bristol, United Kingdom
“I added Lulutox Detox Tea to my wellness routine after looking for a herbal option that felt sustainable. The tea format makes it easy to stay consistent, and it pairs well with my focus on mindful eating and hydration. It doesn’t feel harsh or disruptive, which is important to me when choosing wellness products.”

Visit The Official Lulutox Detox Tea Website To Read UK Customer Reviews About Lulutox Tea!

Is Lulutox Detox Tea Legit or Worth Considering?

Assessing the legitimacy of a wellness product such as LuluTox Detox Tea requires examining its formulation structure, transparency, intended function, and alignment with established herbal wellness practices. From a product design perspective, Lulutox Detox Tea follows a conventional herbal tea framework that has been widely used in digestive and detox-focused wellness categories for decades.

The formulation is built around plant-based ingredients commonly referenced in traditional herbal systems and contemporary wellness literature. These botanicals are typically associated with digestive balance, metabolic support, and internal cleansing functions. Importantly, the tea is positioned as a supportive beverage rather than a therapeutic or pharmaceutical solution, which aligns with regulatory expectations for herbal wellness products.

Lulutox Detox Tea also follows a tea-based delivery model, a format recognized for its gradual absorption and hydration-driven support. This approach reflects established industry standards that prioritize consistency and tolerability over aggressive intervention. The absence of synthetic stimulants or chemical additives further supports its positioning within the natural wellness segment.

Transparency in product purpose is another indicator of legitimacy. Lulutox Detox Tea does not present itself as a rapid or extreme detox solution. Instead, it emphasizes routine use as part of a balanced lifestyle, which aligns with prevailing wellness guidance around sustainable metabolic and digestive support.

From a market standpoint, the product’s distribution through official online website and its structured presentation indicate adherence to standard manufacturing and quality-control practices. While individual outcomes may vary, the formulation logic, delivery method, and positioning suggest that Lulutox Detox Tea meets the baseline criteria expected of a legitimate herbal wellness beverage.

Is Lulutox Detox Tea right for your wellness goals? Here’s what the formulation is designed to do.

Why Lulutox Tea Is Highly Recommended

Within informational and industry-focused wellness discussions, Lulutox Detox Tea is frequently highlighted for its formulation approach and alignment with contemporary detox tea design principles. The product’s recommendation stems primarily from its balanced composition, functional clarity, and compatibility with daily wellness routines rather than from exaggerated claims or short-term performance narratives.

One of the key reasons Lulutox Tea is often referenced positively is its emphasis on botanical synergy. Rather than relying on a single dominant ingredient, the formulation integrates multiple herbs traditionally associated with digestion, metabolism, and detox support. This multi-ingredient structure reflects best practices in herbal blending, where complementary actions are prioritized over isolated effects.

The tea-based delivery format also contributes to its favorable positioning. Herbal teas are widely regarded as one of the most accessible and gentle methods of botanical intake. Lulutox Tea leverages this format to promote hydration while delivering functional plant compounds, aligning with holistic wellness frameworks.

Another factor is its suitability for routine use. The formulation avoids excessive stimulant content and is structured to be consumed consistently, which supports long-term wellness objectives rather than short-lived interventions. This design aligns with growing industry emphasis on sustainable health habits.

Additionally, the product’s clear positioning as a wellness support beverage—rather than a medical or pharmaceutical solution—adds to its credibility. This clarity helps set appropriate expectations and supports responsible usage.

Collectively, these factors contribute to why Lulutox Tea is frequently referenced as a well-structured herbal detox option within informational wellness content.

Final Takeaway: Understanding Lulutox Detox Tea in Today’s Wellness Market

Lulutox Detox Tea reflects a broader shift within the wellness industry toward plant-based, routine-friendly detox solutions that emphasize balance over intensity. As consumer interest continues to move away from extreme cleansing methods, herbal teas designed for daily use have gained renewed relevance.

At its core, LuluTox Detox Tea is built around traditional herbal principles adapted to modern wellness expectations. Its formulation prioritizes digestive support, metabolic balance, and internal cleansing through a carefully selected blend of botanicals delivered in a tea format. This approach aligns with long-standing practices while maintaining contemporary standards for transparency and usability.

The product’s positioning within the market avoids overstated promises and instead focuses on supportive wellness functions. By emphasizing hydration, botanical synergy, and consistent use, Lulutox Detox Tea fits into lifestyle-based wellness strategies rather than short-term detox cycles.

From a market perspective, the tea’s structured formulation, official distribution channels, and clear functional intent place it firmly within the mainstream herbal detox category. It represents an example of how traditional herbal concepts are being refined for modern consumers seeking sustainable wellness tools.

In summary, Lulutox Detox Tea serves as a case study in contemporary detox tea design—balancing traditional herbal knowledge with modern expectations for safety, consistency, and daily integration.

For more information on Lulutox Tea, educational content, and direct purchasing, visit the official Lulutox Tea website

Contact Information

Brand: LuluTox Detox Tea
Website: https://lulutox-official.com
Email: support@lulutox.com
Phone: +1 (888) 828-8952
Mailing Address: 3979 Albany Post Road, Ste 2, Unit #2277, Hyde Park, NY 12538

Disclaimers

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with the official source before making a purchase decision.

FDA Disclaimer: Lulutox Tea is a herbal tea and has not been evaluated by the U.S. Food and Drug Administration (FDA). It is not intended to diagnose, treat, cure, or prevent any disease.

Health Disclaimer: The information provided in this article is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional before beginning any new supplement, especially if you have a medical condition or are taking prescription medication.

Results Disclaimer: Individual results may vary. Some Australia and United Kingdom users report noticeable benefits, while others experience little to no change. Factors such as diet, lifestyle, and overall health can influence outcomes.

Pricing Disclaimer: Product prices, bundles, and promotions for Lulutox Tea are subject to change at any time without notice. Always check the official website for the most current details.

Related Link
Best Semaglutide For Weight Loss

Alvotech Secures Term Loan Facility of USD 100 Million




Alvotech Secures Term Loan Facility of USD 100 Million

• USD 100 million senior term loan facility with a 2-year maturity
• Strengthens liquidity to support execution across Alvotech’s R&D pipeline and global product launches through 2026
• Led by GoldenTree Asset Management

REYKJAVIK, Iceland, Dec. 31, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a USD 100 million senior term loan facility with maturity in December 2027 aimed at strengthening liquidity and supporting the execution of Alvotech’s strategic priorities in 2026.

“This USD 100 million financing underscores the long-term commitment of our financing partners at GoldenTree and their alignment with Alvotech’s strategy,” said Robert Wessman, Chairman and CEO of Alvotech. “Their support strengthens our ability to execute on our growth plans, invest in R&D, and deliver high-quality biosimilars to patients worldwide.”

With the transaction, led by GoldenTree Asset Management, Alvotech secures financing from investors who share the Company’s confidence in its ability to execute, and the scale, quality and commercial potential of its biosimilar product pipeline. Alvotech remains committed to advancing its R&D pipeline, which currently includes 30 products in development and ranks among the most valuable biosimilar portfolios in the industry. In parallel, the Company continues to expand its production capacity and strengthen its supply chain to support four new global product launches through 2026.

The transaction, a senior term loan facility in an aggregate principal amount of USD 100 million, bears an interest rate of 12.50%, payable monthly in cash, and has a maturity date of 2 years. The transaction replaces the Company’s previously disclosed working capital facility (ABL) and provides Alvotech with access to the full USD 100 million throughout the term of the loan. This structure offers enhanced operational flexibility.

This term loan facility follows the successful arrangement of a strategic refinancing transaction maturing in June 2029, also led by GoldenTree Asset Management, as announced in June 2024. In addition, Alvotech announced in June 2025 the repricing of its existing facility to an interest rate of SOFR plus 6.0% per annum, equivalent to approximately 9.8% based on the 30-day average SOFR rate of ~3.8%

Further reinforcing its capital structure, Alvotech recently announced the successful placing of USD 108 million senior unsecured convertible bonds due 2030. Together these transactions position the Company to maintain its leading position and investment into its biosimilar development pipeline.

For further information, please contact:

Media
Benedikt Stefansson, VP Investor Relations and Global Communications
Sarah Macleod, Head of Global Communications
alvotech.media@alvotech.com

Investor Relations
Balaji Prasad, Chief Strategy Officer
Patrik Ling, VP Investor Relations Scandinavia (SE)
Benedikt Stefansson, VP Investor Relations and Global Communications (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira^® (adalimumab), Stelara^® (ustekinumab), Simponi^® (golimumab), Eylea^® (aflibercept) and Prolia^®/Xgeva^® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Alvotech Secures Term Loan Facility of USD 100 Million




Alvotech Secures Term Loan Facility of USD 100 Million

• USD 100 million senior term loan facility with a 2-year maturity
• Strengthens liquidity to support execution across Alvotech’s R&D pipeline and global product launches through 2026
• Led by GoldenTree Asset Management

REYKJAVIK, ICELAND (December 31, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a USD 100 million senior term loan facility with maturity in December 2027 aimed at strengthening liquidity and supporting the execution of Alvotech’s strategic priorities in 2026.

“This USD 100 million financing underscores the long-term commitment of our financing partners at GoldenTree and their alignment with Alvotech’s strategy,” said Robert Wessman, Chairman and CEO of Alvotech. “Their support strengthens our ability to execute on our growth plans, invest in R&D, and deliver high-quality biosimilars to patients worldwide.”

With the transaction, led by GoldenTree Asset Management, Alvotech secures financing from investors who share the Company’s confidence in its ability to execute, and the scale, quality and commercial potential of its biosimilar product pipeline. Alvotech remains committed to advancing its R&D pipeline, which currently includes 30 products in development and ranks among the most valuable biosimilar portfolios in the industry. In parallel, the Company continues to expand its production capacity and strengthen its supply chain to support four new global product launches through 2026.

The transaction, a senior term loan facility in an aggregate principal amount of USD 100 million, bears an interest rate of 12.50%, payable monthly in cash, and has a maturity date of 2 years. The transaction replaces the Company’s previously disclosed working capital facility (ABL) and provides Alvotech with access to the full USD 100 million throughout the term of the loan. This structure offers enhanced operational flexibility.

This term loan facility follows the successful arrangement of a strategic refinancing transaction maturing in June 2029, also led by GoldenTree Asset Management, as announced in June 2024. In addition, Alvotech announced in June 2025 the repricing of its existing facility to an interest rate of SOFR plus 6.0% per annum, equivalent to approximately 9.8% based on the 30-day average SOFR rate of ~3.8%

Further reinforcing its capital structure, Alvotech recently announced the successful placing of USD 108 million senior unsecured convertible bonds due 2030. Together these transactions position the Company to maintain its leading position and investment into its biosimilar development pipeline.

For further information, please contact:

Media
Benedikt Stefansson, VP Investor Relations and Global Communications
Sarah Macleod, Head of Global Communications
alvotech.media@alvotech.com

Investor Relations
Balaji Prasad, Chief Strategy Officer
Patrik Ling, VP Investor Relations Scandinavia (SE)
Benedikt Stefansson, VP Investor Relations and Global Communications (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing




Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR 
FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing (the “Offering”), previously announced on November 6, 2025, to $858,000 and the closing of the fourth and final tranche (the “Fourth Tranche”). Gross proceeds from the Fourth Tranche totaled CAD $117,501 from the sale of 1,678,586 units (the “Units”) at an issue price of CAD $0.07 per Unit. The closing of the Fourth Tranche brings the financing to a total of CAD $857,001 from the sale of 12,242,872 Units, including the closing of previous tranches on November 14, 2025, November 28, 2025 and December 23, 2025. The Offering is now closed.

Certain insiders of the Company participated in the Fourth Tranche of the Offering in the amount of $32,501. The participation by insiders in the Fourth Tranche of the Offering constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (”MI 61-101”). The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the Units purchased by insiders, nor the consideration for the Units paid by such insiders, exceeded 25% of the Company’s market capitalization. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Fourth Tranche of the Offering, which the Company deems reasonable in the circumstances as the details of the participation by insiders of the Company were not settled until shortly prior to closing the Fourth Tranche of the Offering and the Company wished to complete the Fourth Tranche of the Offering in an expeditious manner.

The Company did not pay any cash finder’s fees pertaining to the Fourth Tranche of the Offering.

The Company will use the proceeds of the Offering towards advancing its Alzheimer’s Disease (“AD”) program including the opening of its first U.S. AD clinic, general and administrative expenses and for working capital purposes.

The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration

For more information please contact:

Christopher J. Moreau
CEO
Algernon Health Inc.
604.398.4175 Ext 701
cjmoreau@algernonhealth.com

https://www.algernonhealth.com/

About Algernon Health  

Algernon Health is a Canadian healthcare company focused on the provision of brain optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s Disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA LLC, that will oversee all U.S. neuroimaging operations.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to planned brain-specific neuroimaging PET scanning clinic opening timelines, planned financings in the Company and its subsidiary and the closings of additional tranches thereof, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

River Oaks Treatment Center Offers Expanded Mental Health Services as the New Year Brings Increased Focus on Wellness




River Oaks Treatment Center Offers Expanded Mental Health Services as the New Year Brings Increased Focus on Wellness

RIVERVIEW, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) — The start of a new year often brings reflection, resolve, and the hope for meaningful change. For many Americans, those resolutions center on wellness, and increasingly, on mental health. With more than one in five adults in the U.S. experiencing mental illness across the nation, access to quality mental health care has never been more critical for those ready to take the first step toward healing. In response to this growing need, River Oaks Treatment Center has expanded access to care by offering comprehensive primary mental health services for individuals seeking treatment near Tampa, Florida.

“Florida faces one of the most urgent mental health crises in the nation, ranking second in the nation in prevalence of mental illness while also contending with a notable shortage of mental health services available across the state,” said Chris Bailey, Executive Director, River Oaks Treatment Center. “The opening of River Oaks’ inpatient mental health unit represents a meaningful step toward closing this gap and increasing access to lifesaving care.”

River Oaks Treatment Center has long been recognized for its expertise in treating addiction and co-occurring disorders. Last year, the organization broadened its mission to include specialized care for individuals with primary mental health diagnoses. This expansion was designed to serve the thousands of Floridians who struggle to find timely, effective treatment.

The inpatient mental health facility in Florida provides individualized, evidence-based treatment for conditions such as major depressive disorder, anxiety disorders, and post-traumatic stress disorder (PTSD). For patients experiencing co-occurring issues with substance use or addiction, integrated care is available to address both mental health and substance-related challenges simultaneously.

River Oaks’ comprehensive mental health program is designed not only to stabilize individuals during a difficult moment but to help them build the skills and confidence needed for long-term well-being.

“Through personalized treatment plans, we empower patients to actively manage their mental health, strengthen resilience, and move forward with greater independence and hope,” said Bailey. “As the New Year begins, River Oaks Treatment Center remains committed to helping individuals turn resolutions into lasting change.”

About River Oaks Treatment Center

River Oaks Treatment Center, located in Riverview, FL, serves the Tampa area and individuals nationwide with evidence-based addiction and mental health treatment. We provide a full continuum of inpatient and outpatient services for individuals facing substance use and co-occurring mental health disorders. We believe in the power of recovery and are committed to restoring hope, empowering individuals and families, and breaking the stigma of addiction. Our specialized programs, including a residential primary mental program and tailored support for Veterans, offer a strong foundation for lasting recovery that transforms lives. River Oaks Treatment Center is part of American Addiction Centers, a national leader in addiction treatment. Learn more at riveroakstreatment.com.

Contact:

Amanda Lautieri
Brand & Communications Manager
ALautieri@ContactAAC.com

Laguna Treatment Center Strengthens Clinical Team with New Behavioral Health Therapist




Laguna Treatment Center Strengthens Clinical Team with New Behavioral Health Therapist

ALISO VIEJO, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) — Laguna Treatment Center, a leading drug and alcohol rehab in Orange County, has added Tanya L. Hauer, MSW, ACSW, to its team. A clinically trained behavioral health therapist and group facilitator, Hauer brings specialized experience in trauma-informed care, nervous system regulation, and experiential therapies. Her professional expertise, combined with personal experience in long-term recovery, enhances the depth of clinical care offered at the facility for those seeking rehab in Southern California.

“Recovery is deeply personal, and it requires both skill and empathy,” said Trace Swartzfager, Executive Director of Laguna Treatment Center. “Tanya brings both to her work, and we’re grateful to have her join our team of dedicated professionals who are among the most qualified in the industry and deeply committed to compassionate care.”

Hauer’s background includes work in residential treatment, school-based settings, and community mental health, where she has led process groups and psychoeducation programming, including somatic-informed approaches, for emotional awareness, resilience, and sustainable recovery. She is also an EAGALA-certified equine-assisted psychotherapy practitioner and certified yoga instructor.

At Laguna Treatment Center, Hauer will support the center’s existing equine therapy and yoga therapy offerings. The center partners with Brave Grace, an equine-assisted psychotherapy provider, to deliver trauma-informed treatment that uses the horse-human connection to foster insight, trust and healing.

“Recovery is not just about stopping a behavior,” said Hauer. “It’s about rebuilding trust in oneself, learning how to regulate the nervous system, and discovering that healing is possible even after years of pain. As someone in long-term recovery, this work is deeply personal for me. I’m honored to support individuals during such an important stage in their lives.”

About Laguna Treatment

Laguna Treatment Center, located in Aliso Viejo, CA, serves the Orange County area and individuals nationwide with evidence-based addiction and mental health treatment. We provide residential treatment services for individuals facing substance use and co-occurring mental health disorders. We believe in the power of recovery and are committed to restoring hope, empowering individuals and families, and breaking the stigma of addiction. Our specialized care offers a strong foundation for lasting recovery that transforms lives. Laguna Treatment Center is part of American Addiction Centers, a national leader in addiction treatment. Learn more at lagunatreatment.com.

Contact:
Joy Sutton, VP of Brand and Communications
American Addiction Centers
jsutton@contactaac.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c027b62e-d29e-4515-8ea1-ea31b1a89b6a

New Year, New Mission: Oxford Treatment Center Empowers Veterans to Reclaim Their Lives in 2026




New Year, New Mission: Oxford Treatment Center Empowers Veterans to Reclaim Their Lives in 2026

ETTA, Miss., Dec. 31, 2025 (GLOBE NEWSWIRE) — Veterans face substance use disorders at disproportionately high rates. More than one in ten U.S. Veterans seeking care with the V.A. meets the criteria for a substance use disorder, a statistic that highlights a serious and ongoing public health concern. For many Veterans, addiction is further complicated by co-occurring mental health conditions such as depression, anxiety, and post-traumatic stress disorder, creating significant barriers to recovery.

As the New Year marks a season of reflection and renewed commitment, Oxford Treatment Center wants Veterans to know it is available as a resource for those ready to pursue meaningful change in 2026 and beyond. The Mississippi rehab offers specialized, trauma-informed care tailored to the unique experiences of those who have served and is designated as a “Veteran Ready” organization by PsychArmor, a recognition of the center’s commitment to military cultural competency and Veteran-informed care.

“The experiences Veterans carry are often unlike anything the average civilian has faced,” said Paige Havens, Executive Director of Oxford Treatment Center. “We recognize that reality and have taken deliberate steps to ensure Veterans feel fully supported throughout treatment. From specialized therapeutic groups to dedicated Veteran housing, we foster an environment where our Veteran patients feel understood, respected, and surrounded by peers who share similar experiences.”

Veterans receiving care at the Mississippi rehab facility participate in a comprehensive treatment program that addresses issues commonly affecting the Veteran community, including:

• Anger management.
• Stress and hypervigilance.
• Understanding and managing depression and anxiety.
• Emotional regulation.
• Suicide prevention.
• The impact of post-traumatic stress disorder.

“We know that far too many Veterans struggle in silence after their service ends,” Havens added. “We want to be a lifeline to our nation’s heroes, letting them know help is available and they are not alone.”

Oxford Treatment Center offers a full continuum of care, including medical detoxification, residential treatment, and multiple levels of outpatient treatment for Veterans, including those eligible for V.A. community care.

About Oxford Treatment Center

Oxford Treatment Center, located in Etta, MS, with outpatient locations in Oxford and Southaven, serves Mississippi and the Memphis area, as well as individuals nationwide with evidence-based addiction and mental health treatment. We provide a full continuum of inpatient and outpatient services, as well as sober living, for individuals facing substance use and co-occurring mental health disorders. We believe in the power of recovery and are committed to restoring hope, empowering individuals and families, and breaking the stigma of addiction. Our specialized programs, including tailored support for Veterans, offer a strong foundation for lasting recovery that transforms lives. Oxford Treatment Center is part of American Addiction Centers, a national leader in addiction treatment. Learn more at oxfordtreatment.com.

Contact:

Amanda Lautieri
Brand & Communications Manager
ALautieri@ContactAAC.com

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement




Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine.

Valneva´s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accelerating access for regions most affected by the disease. 

Supporting access to the vaccine in low-and-middle-income countries (LMICs) falls within the framework of the funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union¹.  

About Chikungunya
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years¹.
In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas². Between 2013 and 2023, more than 3.7 million cases were reported in the Americas³ and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.⁴

About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

About CEPI
CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic disease threats and enable equitable access to them. CEPI has supported the development of more than 70 vaccine candidates or platform technologies against multiple known high-risk pathogens and is advancing the development of rapid response platforms for vaccines against a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.

About Horizon Europe
Horizon Europe — #HorizonEU — is the European Union’s flagship Research and Innovation programme, part of the EU-long-term Multiannual Financial Framework (MFF) with a budget of €95,5 billion to spend over a seven-year period (2021-2027).  Under Horizon Europe, health research will be supported with the aim to find new ways to keep people healthy, prevent diseases, develop better diagnostics and more effective therapies, use personalised medicine approaches to improve healthcare and wellbeing, and take up innovative health technologies, such as digital ones.

About Serum Institute of India Private Limited 
Serum Institute of India Pvt. Ltd, part of Cyrus Poonawalla Group is a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. Present across 170+ countries, including the US, UK, and Europe, SIIPL holds the distinction of being the world’s largest vaccine manufacturer. SIIPL’s multifunctional production and one-of-the-largest facilities in Hadapsar & Manjari, Pune, with an annual capacity of 4 billion doses, has saved over 30 million lives over the years.  
Founded in 1966, SIIPL’s primary mission is to produce life-saving immunobiological drugs, with a particular emphasis on affordability and accessibility. Guided by a strong commitment to improving global health, the company has played a pivotal role in reducing the prices of essential vaccines, such as Diphtheria, Tetanus, Pertussis, HIB, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, they are the manufacturers of ‘Pneumosiil,’ the world’s most affordable PCV, ‘Cervavac’ the first indigenous qHPV vaccine in India, and R21/Matrix-M™, the second Malaria vaccine to be authorized for use in children in malaria-endemic regions, ‘MenFive’, the first in the world Pentavalent (ACYWX) Meningococcal Polysaccharide Conjugate Vaccine, approved and WHO-prequalified for use in the pediatric population. Moreover, SIIPL has been at the forefront of the global fight against COVID-19, delivering over 2 billion doses of the COVID-19 vaccine worldwide. 
To further expand its global presence and ensure widespread vaccine availability, SIIPL has established Serum Life Sciences Ltd, a subsidiary in the UK and Serum Inc., a subsidiary in the US. Through relentless pursuit of innovation, SII continues to champion the cause of affordable vaccines, making a positive impact on the lives of millions worldwide. www.seruminstitute.com 

Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

1 https://jvi.asm.org/content/jvi/88/20/11644.full.pdf
2 https://cmr.asm.org/content/31/1/e00104-16
3 PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year 2013-2017). https://www.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-en.html. Last accessed 01 Aug 2023.
4 Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas (who.int)

Attachment

• 2025_12_31_VLA_SII_Termination_PR_EN_Final